Literature DB >> 4820641

Significance of intravascular coagulation and fibrinolysis in acute hepatic failure.

P Hillenbrand, S P Parbhoo, A Jedrychowski, S Sherlock.   

Abstract

Twenty-two patients with acute hepatic failure were studied to determine the incidence and magnitude of intravascular coagulation and fibrinolysis and their relation to the severity of bleeding and prognosis. The mean platelet count, Thrombotest, plasminogen activator, and plasminogen were reduced; the reduction in fibrinogen was not statistically significant. Fibrin/fibrinogen degradation products were only moderately increased. Hepatic fibrin deposition was not extensive, being present in 11 of 22 hepatic sections, more in areas of confluent necrosis than in the sinusoids. The combination of increased fibrin/fibrinogen degradation products with decreased plasminogen activator, plasminogen, and thrombocytopenia is consistent with a diagnosis of intravascular coagulation and secondary local fibrinolysis. However, neither of these processes was severe. Severity of bleeding was related only to plasminogen levels and prognosis only to Thrombotest levels. There was no relation between hepatic histological and haematological findings. Heparin therapy is not indicated in the routine management of acute hepatic failure, as intravascular coagulation is not severe and heparin may itself cause massive bleeding.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4820641      PMCID: PMC1412899          DOI: 10.1136/gut.15.2.83

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

1.  JAUNDICE AND ITS RELATION TO THERAPEUTIC AGENTS.

Authors:  G C COOK; S SHERLOCK
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

2.  Studies on the character and staining of fibrin.

Authors:  A C LENDRUM; D S FRASER; W SLIDDERS; R HENDERSON
Journal:  J Clin Pathol       Date:  1962-09       Impact factor: 3.411

3.  Cellular localization of profibrinolysin (plasminogen).

Authors:  M I BARNHART; J M RIDDLE
Journal:  Blood       Date:  1963-03       Impact factor: 22.113

4.  Fibrin degradation products in normal and abnormal pregnancy and parturition.

Authors:  J Bonnar; J F Davidson; C F Pidgeon; G P McNicol; A S Douglas
Journal:  Br Med J       Date:  1969-07-19

5.  Estimation of the activator of fibrinolysis by means of the euglobulin test.

Authors:  T Januszko; L Dubińska
Journal:  Acta Med Pol       Date:  1965

6.  An electron microscopic study of thrombin-induced disseminated intravascular coagulation.

Authors:  W Margaretten; I Csavossy; D G McKay
Journal:  Blood       Date:  1967-02       Impact factor: 22.113

7.  Diagnosis of diffuse intravascular clotting: its relation to secondary fibrinolysis and treatment with heparin.

Authors:  A J Johnson; C Merskey
Journal:  Thromb Diath Haemorrh Suppl       Date:  1966

8.  Effects of fibrinogen degradation products on platelets and coagulation.

Authors:  M J Larrieu; V J Marder; S Inceman
Journal:  Thromb Diath Haemorrh Suppl       Date:  1966

9.  Ischaemic enterocolitis: an expression of the intravascular coagulation syndrome.

Authors:  R Whitehead
Journal:  Gut       Date:  1971-11       Impact factor: 23.059

10.  Early and intensive therapy of intravascular coagulation in acute liver failure.

Authors:  M O Rake; P T Flute; K B Shilkin; M L Lewis; J Winch; R Williams
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

View more
  20 in total

1.  A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.

Authors:  Y Yamaguchi; K Okabe; J Liang; F Matsumura; H Ohshiro; K Ishihara; T Matsuda; M Takeya; J I Kuratsu; K Mori; S Yamada; M Ogawa
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

2.  Behaviour of 125I-fibrinogen and 131I-albumin in experimental galactosamine-induced hepatitis.

Authors:  I Mahn; H Merkel; E L Sattler; G Müller-Berghaus
Journal:  Gut       Date:  1977-07       Impact factor: 23.059

Review 3.  Haemostatic problems in liver disease.

Authors:  D A Kelly; E G Tuddenham
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

Review 4.  Algorithms for managing coagulation disorders in liver disease.

Authors:  R Todd Stravitz
Journal:  Hepatol Int       Date:  2018-07-31       Impact factor: 6.047

5.  An experimental animal model of fulminant hepatic failure in pigs.

Authors:  Kuhn Uk Lee; Long-xian Zheng; Yong Beom Cho; Ki-Ho Kim; Jongwon Ha; Kyung-Suk Suh; Sung Eun Jung
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

Review 6.  A minireview of the pathogenesis of acute leptospirosis.

Authors:  R Higgins
Journal:  Can Vet J       Date:  1981-09       Impact factor: 1.008

Review 7.  Indications and criteria for liver transplantation for fulminant hepatic failure.

Authors:  Kenji Fujiwara; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

8.  Usefulness of antithrombin III and alpha 2-plasmin inhibitor in early differentiation of fulminant hepatitis and severe form of acute hepatitis.

Authors:  S Sato; A Murakami; T Yoshida; T Kashiwabara; K Suzuki; I Kaito
Journal:  Gastroenterol Jpn       Date:  1983-04

9.  Antithrombin III concentrate in the treatment of fulminant hepatic failure.

Authors:  K Fujiwara; K Okita; K Akamatsu; H Abe; Y Tameda; T Sakai; N Inoue; K Kanai; N Aoki; H Oka
Journal:  Gastroenterol Jpn       Date:  1988-08

10.  Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III.

Authors:  K Fujiwara; I Ogata; Y Ohta; K Hirata; Y Oka; S Yamada; Y Sato; N Masaki; H Oka
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.